Clinical trials: Chronic Infection
Rhinitis, Urticaria
Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria
Eligible patients will be prescribed Desloratadine 1 tablet of 5 mg once daily. Patients will be asked to follow-up for a final visit after 14 days (Day 15) where the safety, tolerability and clinical efficacy will be measured.
- Trial name
- Aerius (NCT00724698)
- Testing
- Desloratadine
- Volunteers
- 3,011 people
- Sponsor
- Organon and Co
Chronic Hepatitis C, Hemophilia
Viral Kinetics in HCV Clearance in Subjects With Hemophilia
This study will examine viral dynamic responses in subjects with chronic hepatitis C and hemophilia when treated with pegylated interferon + ribavirin and telaprevir.
- Trial name
- HCV/Hemophil (NCT01704521)
- Testing
- PegInterferon, Ribavirin, Telaprevir
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Kenneth Sherman
Hepatitis C, Chronic Kidney Disease
Effect of Harvoni on Proteinuria and eGFR in Hepatitis C Virus Associated Chronic Kidney Disease (CKD)
Treatment protocol to see if people with hepatitis C (HCV) and chronic kidney disease (CKD) who are treated with Harvoni for 12 weeks have improvements in their kidney disease.
- Trial name
- NCT02503735
- Testing
- Sofosbuvir/Ledipasvir FDC
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Massachusetts General Hospital
Posterior Uveitis, Intermediate Uveitis
Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis
Phase 3, multi-center, randomized, masked, controlled study to evaluate the safety and efficacy of an injectable fluocinolone acetonide intravitreal (FAI) insert for the management of subjects with chronic non-infectious uveitis…
- Conditions
- Posterior Uveitis, Intermediate Uveitis, Panuveitis
- Trial name
- NCT02746991
- Testing
- FAI Insert
- Where
- 15 sites in India
- Volunteers
- 153 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Hepatitis C, Chronic
Boceprevir-based Therapy to Rescue HCV Genotype 1/HBV Infected Patients Refractory to Combination Therapy
The aim of this study is to explore the efficacy and safety of boceprevir -based triple therapy to rescue HCV genotype 1 (HCV GT1)/HBV dually infected patients refractory to previous peginterferon (PEG-IFN) plus ribavirin (RBV)…
- Trial name
- BOLERO-CB (NCT02060058)
- Testing
- Stop trial intervention for boceprevir, PEG-IFN and RBV
- Where
- Taiwan
- Volunteers
- 12 people
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
This pilot phase II trial studies how well giving vorinostat, tacrolimus, and methotrexate works in preventing graft-versus-host disease (GVHD) after stem cell transplant in patients with hematological malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT01789255
- Testing
- vorinostat, tacrolimus, cyclosporine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Hepatitis C, Chronic
A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow Response
This open-label, multi-center study will evaluate the safety and tolerability and the effect on viral activity of a combined PEGASYS and COPEGUS extended therapy in patients with chronic hepatitis C with genotype 1, 2 and 3.
- Trial name
- NCT01033448
- Testing
- COPEGUS, peginterferon alfa-2a [Pegasys]
- Where
- 20 sites in Israel
- Volunteers
- 59 people
- Sponsor
- Hoffmann-La Roche
Chronic Hepatitis C Infection
A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) for Treatment of Chronic Hepatitis C Infection in Treatment-experienced Adults
The purpose of this study is to evaluate the safety and antiviral activity of 3 direct-acting antiviral agents (DAAs; ABT-450/ritonavir/ABT-267 [ABT-450/r/ABT-267; ABT-267 also known as ombitasvir] and ABT-333 [also known as…
- Trial name
- MALACHITE II (NCT01854528)
- Testing
- ABT-450/r/ABT-267, ABT-333, Ribavirin, Pegylated Interferon a-2a (PegINF)
- Volunteers
- 148 people
- Sponsor
- AbbVie
Hepatitis C
Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)
This is a randomized, three-part, open-label trial of grazoprevir (GZR; MK-5172) (100 mg) and uprifosbuvir (UPR; MK-3682) (300 mg or 450 mg), with either elbasvir (EBR; MK-8742) (50 mg) or ruzasvir (RZR; MK-8408) (60 mg), and…
- Trial name
- NCT02332707
- Testing
- Grazoprevir, Uprifosbuvir, Elbasvir
- Volunteers
- 443 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic, Substance Use Disorders
Linkage to Care for Persons With Hep C Infection
Hepatitis C Virus (HCV) infection is an ongoing challenge in the United States, with an estimated 2.4 million individuals living with HCV in 2016.
- Trial name
- NCT05397067
- Testing
- Peer specialist (PS), Incentives, telehealth visits
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Carilion Clinic
Chronic Hepatitis C, Hepatitis C Virus
A Study to Evaluate the Safety and Antiviral Effect of ABT-450/Ritonavir and ABT-530 Coadministered With and Without Ribavirin in Adults With Genotype 3 Hepatitis C (HCV) Infection
The purpose of this study is to evaluate the safety and antiviral effect of ABT-450/r and ABT-530 coadministered with and without Ribavirin in adults with genotype 3 HCV infection.
- Trial name
- NCT02068222
- Testing
- ABT-450/ritonavir (r), ABT-530, Ribavirin (RBV)
- Volunteers
- 10 people
- Sponsor
- AbbVie
Chronic Hepatitis C, Hepatitis C Virus (HCV) Infection
Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
The purpose of this study was to assess the safety, pharmacokinetics, and 4-week rapid virologic response (RVR) of 3 different doses of ABT-267 (also known as ombitasvir) in combination with pegylated interferon/ribavirin…
- Trial name
- NCT01314261
- Testing
- ABT-267, Pegylated interferon (pegIFN), Ribavirin (RBV)
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 37 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hepatitis C, Chronic
Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 Infection
This study examined the influence of ribavirin on the initial virological response in treatment-naïve participants with chronic hepatitis C, genotype 1.
- Trial name
- NCT02716779
- Testing
- Pegylated Interferon (PEG-IFN) alfa-2a, Ribavirin
- Where
- 5 sites in Germany
- Volunteers
- 68 people
- Sponsor
- Hoffmann-La Roche
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
This phase II trial studies how well giving lenalidomide with or without rituximab works in treating patients with progressive or relapsed chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), prolymphocytic…
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
- Trial name
- NCT01419795
- Testing
- lenalidomide, rituximab, pharmacological study
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Fred Hutchinson Cancer Center
Hepatitis C, Chronic
A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection
This study will evaluate the addition of a higher-dose induction treatment period with peginterferon (PEG-IFN) alfa-2a (Pegasys) and ribavirin prior to standard-dose treatment with PEG-IFN alfa-2a and ribavirin, compared to…
- Trial name
- NCT00192647
- Testing
- PEG-IFN alfa-2a, Ribavirin
- Where
- 51 sites in Argentina, Australia and 4 more
- Volunteers
- 896 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
Pharmacokinetics of Boceprevir in Pediatric Subjects With Chronic Hepatitis C Genotype 1 (P07614)
This is a study to determine the pharmacokinetics (PK) and weight-based dose of boceprevir following single oral dose administration in Chronic Hepatitis C Virus (HCV) pediatric participants.
- Trial name
- NCT01425190
- Testing
- Boceprevir
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic HCV Infection
Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection
This study will evaluate the antiviral efficacy of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) plus ribavirin (RBV) or LDV/SOF plus GS-9669 in treatment-naive or treatment-experienced participants with chronic…
- Trial name
- NCT01984294
- Testing
- LDV/SOF, RBV, GS-9669
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Gilead Sciences
Respiratory Tract Diseases, Abnormal Mucus Secretions
A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions
This is a phase 3, multicenter, randomized, rater- and patient-blind, placebo- and active-controlled, 3-arm parallel group clinical trial.
- Trial name
- NCT03843541
- Testing
- N-acetylcysteine (NAC) 600 mg, Ambroxol hydrochloride 30 mg
- Where
- 32 sites in China
- Volunteers
- 333 people
- Sponsor
- Zambon SpA
Chronic Hepatitis C
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C
The interferon-free combination regimen of paritaprevir/r - ombitasvir with or without dasabuvir (ABBVIE REGIMEN) ± ribavirin (RBV) for the treatment of chronic hepatitis C (CHC) has been shown to be safe and effective in…
- Trial name
- 3DUTCH (NCT02817594)
- Where
- 9 sites in Netherlands
- Volunteers
- 51 people
- Sponsor
- AbbVie
Hepatitis C
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection
This study will evaluate the antiviral efficacy, safety, and tolerability of sofosbuvir (SOF) plus ribavirin (RBV) in Japanese participants with chronic genotype 2 hepatitis C virus (HCV) infection.
- Trial name
- NCT01910636
- Testing
- Sofosbuvir, RBV
- Where
- 19 sites in Japan
- Volunteers
- 153 people
- Sponsor
- Gilead Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.